However, it needs to be assessed whether the antagonistic roles of adiponectin and TNF-α continue to exist and to play a pathophysiological role during the progression of the disease to NAFLD-associated HCC (Figure 1); if this is validated, it may have certain preventive and therapeutic perspectives for NAFLD-associated HCC. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.